Precision Medicine in Oncology®

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Latest News

Repotrectinib for NTRK+ Solid Tumors | Image Credit: © Katsyarina – stock.adobe.com
China’s NMPA Accepts sNDA for Repotrectinib for NTRK+ Solid Tumors

April 21st 2025

China’s NMPA has accepted an sNDA for review, seeking the approval of repotrectinib for advanced solid tumors harboring NTRK fusions.

Five Under 5: Top Oncology Videos for the Week of 4/13
Five Under 5: Top Oncology Videos for the Week of 4/13

April 20th 2025

Image Credit:©Sebastian Kaulitzki – stock.adobe.com
NDA Accepted in China for Zurletrectinib for NTRK Gene Fusion+ Advanced Solid Tumors

April 16th 2025

The top 5 OncLive videos of the week cover insights in myelofibrosis, chronic lymphocytic leukemia, colorectal cancer, breast cancer, and ovarian cancer.
Five Under 5: Top Oncology Videos for the Week of 4/6

April 13th 2025

Nivolumab/ipilimumab is approved for dMMR/MSI-H mCRC and unresectable or metastatic HCC, larotrectinib wins full approval in NTRK+ solid tumors, and more.
The OncFive: Top Oncology Articles for the Week of 4/6

April 12th 2025

Video Series
Video Interviews
Podcasts

More News